Kynurenine pathway metabolite

The **kynurenine pathway** is the principal route of tryptophan catabolism in mammals and leads to the production of several biologically active metabolites collectively known as **kynurenines**. These include kynurenine itself, kynurenic acid, xanthurenic acid, quinolinic acid, 3-hydroxykynurenine, anthranilic acid and others. The first step is catalyzed by indoleamine 2,3-dioxygenase (IDO1/IDO2) or tryptophan 2,3-dioxygenase (TDO), converting tryptophan into N-formyl-L-kynurenine and then to L-kynurenine. Downstream enzymes further process these intermediates into compounds with diverse biological activities. Kynurenines play key roles in regulating immune responses—some are immunosuppressive while others are pro-inflammatory—and influence neuronal excitability by acting on glutamate receptors such as NMDA receptors. They also contribute to energy metabolism through NAD+ biosynthesis[3][4]. Dysregulation of this metabolic network has been implicated in a wide range of diseases including neurodegenerative disorders like Alzheimer's and Huntington's disease; psychiatric conditions such as depression and schizophrenia; cardiovascular diseases; cancer progression via tumor-induced immunosuppression; muscle atrophy associated with inflammation; among others[1][4][6]. While individual enzymes within this pathway—such as IDO1—are considered therapeutic targets for drug development due to their role in modulating immune tolerance especially in cancer therapy,[1] "kynurenine pathway metabolites" refers collectively to small molecules rather than a single molecular target. Therefore it is not accurate to consider them together as one therapeutic target. The **kynurenine/tryptophan ratio** serves as a biomarker for monitoring activity along this metabolic route and can reflect inflammatory status or predict disease risk/progression[1]. Safety concerns when targeting this system include potential disruption of normal immune homeostasis or induction of neurotoxic effects if metabolite balance shifts unfavorably[5]. In summary: "Kynurenine pathway metabolites" describes a family of small-molecule products from tryptophan degradation—not a single protein/gene/receptor/enzyme—and should not be treated as an individual druggable target but rather understood within its broader biochemical context.

Other names

KynureninesTryptophan metabolitesKP metabolites

Enzyme inhibition or activation within the kynurenine pathway (e.g., IDO1 inhibitors reduce immunosuppressive kynurenines)